NLRP3 and cancer: PharmMapper has been successful in previous studies such as for predicting the anti-inflammatory effects of Shufengjiedu Capsule10, antitumor evaluation of some new 1,2,4-triazines27, inhibition of lipopolysaccharides-induced nucleotide-binding domain leucine-rich repeats family pyrin domain-containing 3 (NLRP3) inflammasome activation by hydroxysafflor yellow A12, identification of a potential target for Capsaicin13, identification of anti-cancer targets for Punica granatum14, and several similar targets15,16,40.